ProCE Banner Activity


PARP Inhibitors in Prostate Cancer: Improving Patient Outcomes Through Precision Therapy

Slideset

Learn how the APP’s role is evolving in caring for patients receiving PARP inhibitors for prostate cancer, from determining eligibility to patient counseling to managing treatment-related adverse events.

Released: April 19, 2023

Share

Faculty

Frank dela Rama

Frank dela Rama, RN, MS, AOCNS, AGN-BC

Clinical Nurse Specialist, Oncology/Geonomics
Palo Alto Medical Foundation
Sutter Health
Palo Alto, California 

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC